Skip to main content

Drug Interactions between Nexavar and vismodegib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

SORAfenib vismodegib

Applies to: Nexavar (sorafenib) and vismodegib

MONITOR: Coadministration with inhibitors of P-glycoprotein may increase the plasma concentrations of vismodegib, which has been shown in vitro to be a substrate of the efflux transporter. The potential for increased pharmacologic effects of vismodegib, including adverse effects such as muscle spasm, alopecia, dysgeusia/ageusia, weight loss, fatigue, nausea, vomiting, diarrhea, decreased appetite, constipation and arthralgia, should be considered.

MANAGEMENT: Caution is advised if vismodegib is used in combination with P-glycoprotein inhibitors.

References (2)
  1. (2012) "Product Information. Erivedge (vismodegib)." Genentech
  2. Cerner Multum, Inc. (2015) "Canadian Product Information."

Drug and food interactions

Moderate

SORAfenib food

Applies to: Nexavar (sorafenib)

ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of sorafenib. According to the product labeling, sorafenib bioavailability was reduced by 29% when administered with a high-fat meal compared to administration in the fasted state. When given with a moderate-fat meal, bioavailability was similar to that in the fasted state.

MANAGEMENT: To ensure maximal and consistent oral absorption, sorafenib should be taken at least one hour before or two hours after eating.

References (1)
  1. (2005) "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer